RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival…
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT ® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy
Results from an interim analysis featured in…
